China Pharma Univ. EGFR compound 13

China Pharma Univ. EGFR compound 13: sourced facts only. name: "Promising compound 13 can effectively induce degradation of EGFRdel19 with DC50 value of 3.57 nM in HCC-827 cells, but not to other EGFR mutant, wild-type EGFR protein and the same family receptors (HER2 and HER4)." [PMID:35081479]; target: "Promising compound 13 can effectively induce degradation of EGFRdel19 with DC50 value of 3.57 nM in HCC-827 cells, but not to other EGFR mutant, wild-type EGFR protein and the same family receptors (HER2 and HER4)." [PMID:35081479]; developer: "State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China." [PMID:35081479]; modality: "Of note, 13 is the first EGFR-PROTAC to evaluate antitumor effect in vivo, and exhibited excellent antitumor efficacy (TGI = 90%) at a dose of 30 mg/kg without causing observable toxic effects." [PMID:35081479]